Physician profile
James Post
NPI 1265494264
$12,870.54
in general payments reported to CMS, 2019-2025
34 companies · $1,435 in 2025
The $1,435 reported for 2025 was more than what 78% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,134 · 2020: $1,515 · 2021: $1,637 · 2022: $2,127 · 2023: $1,750 · 2024: $1,272 · 2025: $1,435.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,445 · Education: $12.91.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,444.97 |
| Education | $12.91 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,831.74 | 2019-2025 | Repatha, Repatha |
| Abbott Laboratories | $1,576.67 | 2019-2025 | Aveir, Mitraclip, Cardiomems |
| Janssen Pharmaceuticals, INC | $1,466.63 | 2019-2024 | Xarelto |
| Astrazeneca Pharmaceuticals Lp | $1,071.27 | 2019-2025 | Farxiga |
| Novartis Pharmaceuticals Corporation | $825.56 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $745.86 | 2019-2025 | Jardiance |
| E.R. Squibb & Sons, L.L.C. | $744.02 | 2019-2025 | Camzyos, Eliquis |
| Pfizer INC. | $713.79 | 2019-2025 | |
| Amarin Pharma, INC. | $650.29 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $462.35 | 2021-2024 | Verquvo |
| Esperion Therapeutics, INC. | $327.57 | 2020-2025 | Nexletol |
| Sanofi-Aventis U.S. LLC | $293.42 | 2019-2023 | |
| Novo Nordisk INC | $284.49 | 2023-2025 | Ozempic, Wegovy, Rybelsus |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $267.31 | 2019-2024 | Lifevest |
| Boston Scientific Corporation | $239.71 | 2021-2025 | Watchman Access System, Watchman Flx |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $195.19 | 2019 | |
| Lexicon Pharmaceuticals, INC. | $186.17 | 2023-2024 | Inpefa |
| Edwards Lifesciences Corporation | $146.09 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv) |
| Bayer Healthcare Pharmaceuticals INC. | $138.64 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $128.69 | 2019-2025 | Onpattro |
| Regeneron Healthcare Solutions, INC. | $106.37 | 2019-2025 | Evkeeza |
| Medtronic, INC. | $70.92 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $69.27 | 2019-2021 | |
| Actelion Pharmaceuticals US, INC. | $57.43 | 2023-2025 | Opsumit, Uptravi |
| Scpharmaceuticals INC. | $47.68 | 2023-2024 | |
| Kiniksa Pharmaceuticals International, Plc | $41.82 | 2024 | Arcalyst |
| Cvrx, INC. | $35.13 | 2025 | Barostim Neo System |
| Abbvie INC. | $32.09 | 2025 | |
| Biotronik INC. | $22.86 | 2022 | |
| Abiomed | $20.09 | 2024 | Impella |
| Glaxosmithkline, LLC. | $20.02 | 2025 | Arexvy, Shingrix |
| Philips North America LLC | $17.79 | 2023 | |
| Vital Connect, INC | $17.64 | 2023 | Vitalpatch Rtm |
| Lilly USA, LLC | $15.97 | 2025 | Mounjaro, Zepbound |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw James Post listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.